
Opinion|Videos|May 10, 2024
The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer
Focusing on elacestrant, Dr Graff discusses the role of oral SERDs (selective estrogen receptor degraders) in the treatment of patients with ER+/HER2- metastatic breast cancer.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Prescription Access Crisis: 40% of GLP-1 RA Rx Are Unfilled
2
FDA Expands Upadacitinib Label for Treating Inflammatory Bowel Disease
3
Value-Based Care Offers Solutions to Patient Access Challenges: Brian Mulherin, MD
4
New WHO Reports Sounds Alarm on Antimicrobial Resistance
5